Newron starts a PhII schizophrenia study; FDA accepts an NDA from AbbVie;

@FierceBiotech: Q&A: Philips on what's next after the first year of HealthTech. More from FierceMedicalDevices | Follow @FierceBiotech

@JohnCFierce: Zafgen shares crash after second patient in pivotal obesity study dies. Report | Follow @JohnCFierce

@DamianFierce: Knicks Porzingis jersey not yet for sale so I'm just getting his name tattooed on my back as a placeholder. | Follow @DamianFierce

> Italy's Newron Pharmaceuticals has launched a Phase II study with its novel sodium channel blocker, NW-3509, in patients with schizophrenia. Release

> AbbVie ($ABBV) says that the FDA has accepted its NDA for a once-daily, fixed-dose formulation of the components of Viekira Pak (ombitasvir, paritaprevir, and ritonavir tablets; dasabuvir tablets). Release

> Ultragenyx's ($RARE) in-development treatment for a rare bone disease improved symptoms in interim results from a Phase II study, the company said. More

> GlaxoSmithKline ($GSK) launched Nucala, an antibody treatment for severe asthma. News

> Researchers at Rockefeller University have hit on a new approach to treating nicotine addiction that could spark new therapies. Story

Medical Device News

@FierceMedDev: ICYMI yesterday: Boston Sci receives FDA and CE mark approval of its thrombectomy catheter for deep vein thrombosis. Story | Follow @FierceMedDev

@VarunSaxena2: ICYMI from FierceDrugDelivery: AstraZeneca begins dosing in trial of its Bind-partnered cancer candidate. Article | Follow @VarunSaxena2

@EmilyWFierce: $GILD: "Let's not fold to advocacy pressure in 2014." More from the WSJ | Follow @EmilyWFierce

> Syneron Medical bogged down with slumping sales for ultrasound fat-zapping device. Story

> Theranos asked military general for help tamping down 'misinformation' from the DOD. Article

Pharma News

@FiercePharma: FDA approves Seqirus' Fluad, the first U.S. adjuvanted flu vaccine. FierceVaccines story | Follow @FiercePharma

@CarlyHFierce: ICYMI yesterday: Bristol-Myers puts a blockbuster $142K price on new cancer med Empliciti. Article | Follow @CarlyHFierce

> Novo touts SGLT2-topping data for blockbuster Victoza. Story

> GSK jumps on the 'smart inhaler' bandwagon with Ellipta sensor deal. Report

> Americans point fingers at Big Pharma over dramatic drug price increases. Article

Biotech Research News

> UCLA scientist points to pregnancy hormone as a safe, simple MS therapy. Article

> Scripps team partially corrects impact of a cystic fibrosis mutation. More

> Rockefeller researchers study a new approach to controlling nicotine addiction. Story

> BRCA1 is back in the spotlight, this time for Alzheimer's disease. Report

> New class of antimicrobials may be highly potent against MRSA. Article

Vaccines News

> Parents may be misled by inaccurate HPV vaccine websites, report says. Item

> NIAID to bring Chikungunya vaccine into Phase II. Report

> Valneva's C. diff vaccine found to be 'highly immunogenic' in PhII. Article

> Sanofi, Shantha to supply polio vaccines for India's universal immunization scheme. More

> FDA approves Seqirus' Fluad, the first U.S. boosted flu vaccine. Story

Pharma Marketing News

> Novo Nordisk strikes back with SGLT2-beating data on Victoza. Story

> Study finds no shortage of misleading HPV vaccine websites. Item

> Amgen biosim advances toward battle with AbbVie's mega-selling Humira. Report

> Pfizergan headed for top of ad-spend leaderboard--and not just in pharma. Article

> Ex-Sanofi staffer adds new allegations to last year's kickback suit. More

Suggested Articles

Eli Lilly is combining the oncology team at Lilly Research Laboratories with Loxo Oncology and putting a trio of Loxo execs at the helm.

The failure of SAGE-217 to beat placebo wiped more than 50% off Sage’s share price as investors digested the implications of the data.

The data tee Aurinia up to file for FDA approval next year and go on to address a major unmet medical need.